154 related articles for article (PubMed ID: 37555463)
81. Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2-negative Metastatic Breast Cancer.
Smith J; Irwin A; Jensen L; Tedesco K; Misir S; Zhu W; Almonte A; He Y; Xie R; Olivo M; O'Shaughnessy J
Clin Breast Cancer; 2020 Apr; 20(2):160-167. PubMed ID: 31980406
[TBL] [Abstract][Full Text] [Related]
82. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
Rau KM; Ou-Yang F; Chao TC; Kuo YL; Cheng TF; Chao TY; Chen DR; Tzeng YD; Wang BW; Liu CY; Hu MH; Lu YC; Ou WJ; Kuo CH; Chuang CH; Kan JY; Chen FM; Hou MF
Breast Cancer Res Treat; 2018 Aug; 170(3):583-591. PubMed ID: 29623575
[TBL] [Abstract][Full Text] [Related]
83. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
Muss H; Cortes J; Vahdat LT; Cardoso F; Twelves C; Wanders J; Dutcus CE; Yang J; Seegobin S; O'Shaughnessy J
Oncologist; 2014 Apr; 19(4):318-27. PubMed ID: 24682463
[TBL] [Abstract][Full Text] [Related]
84. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.
Aogi K; Iwata H; Masuda N; Mukai H; Yoshida M; Rai Y; Taguchi K; Sasaki Y; Takashima S
Ann Oncol; 2012 Jun; 23(6):1441-8. PubMed ID: 21989327
[TBL] [Abstract][Full Text] [Related]
85. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
Potthoff K; Stötzer O; Söling U; Hansen R; Harde J; Dille S; Nusch A; Marschner N
Clin Breast Cancer; 2020 Jun; 20(3):e315-e326. PubMed ID: 32273207
[TBL] [Abstract][Full Text] [Related]
86. Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
Mukai H; Saeki T; Shimada K; Naito Y; Matsubara N; Nakanishi T; Obaishi H; Namiki M; Sasaki Y
Invest New Drugs; 2015 Feb; 33(1):119-27. PubMed ID: 25242374
[TBL] [Abstract][Full Text] [Related]
87. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Yardley DA; Peacock N; Daniel B; Anz B; Molthrop DC; Shroff SK; Young R; Jankov A; Vander Woude A; Shastry M; Pasek J; DeBusk LM; Hainsworth JD
Breast Cancer Res Treat; 2020 Apr; 180(3):647-655. PubMed ID: 32060783
[TBL] [Abstract][Full Text] [Related]
88. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
Poletti P; Ghilardi V; Livraghi L; Milesi L; Rota Caremoli E; Tondini C
Future Oncol; 2014 Feb; 10(2):233-9. PubMed ID: 24490609
[TBL] [Abstract][Full Text] [Related]
89. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
[TBL] [Abstract][Full Text] [Related]
90. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
Cortes J; Lorca R
Future Oncol; 2011 Mar; 7(3):355-64. PubMed ID: 21375468
[TBL] [Abstract][Full Text] [Related]
91. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies.
O'Shaughnessy J; McIntyre K; Schwartzberg L; Wilks S; Puhalla S; Berrak E; Song J; Vahdat L
Springerplus; 2015; 4():532. PubMed ID: 26413438
[TBL] [Abstract][Full Text] [Related]
92. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
Pérez-Garcia J; Cortés J; Metzger Filho O
Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
[TBL] [Abstract][Full Text] [Related]
93. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study.
Fujisawa Y; Fujimura T; Matsushita S; Yamamoto Y; Uchi H; Otsuka A; Funakoshi T; Miyagi T; Hata H; Gosho M; Kambayashi Y; Aoki M; Yanagi T; Ohira A; Nakamura Y; Maeda T; Yoshino K
Br J Dermatol; 2020 Nov; 183(5):831-839. PubMed ID: 32198756
[TBL] [Abstract][Full Text] [Related]
94. Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Aogi K; Watanabe K; Kitada M; Sangai T; Ohtani S; Aruga T; Kawaguchi H; Fujisawa T; Maeda S; Morimoto T; Sato N; Takao S; Morita S; Masuda N; Toi M; Ohno S
Int J Clin Oncol; 2021 Jul; 26(7):1229-1236. PubMed ID: 33891194
[TBL] [Abstract][Full Text] [Related]
95. Eribulin mesylate (Halaven) for breast cancer.
Med Lett Drugs Ther; 2011 Apr; 53(1362):30-1. PubMed ID: 21502935
[TBL] [Abstract][Full Text] [Related]
96. Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Cadoo KA; Kaufman PA; Seidman AD; Chang C; Xing D; Traina TA
Clin Breast Cancer; 2018 Dec; 18(6):433-440.e1. PubMed ID: 29895438
[TBL] [Abstract][Full Text] [Related]
97. Eribulin: Heavily pretreated breast cancer: uncertain advantages, excessive adverse effects.
Prescrire Int; 2012 Feb; 21(124):37-8. PubMed ID: 22413716
[TBL] [Abstract][Full Text] [Related]
98. Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment.
Islam B; Lustberg M; Staff NP; Kolb N; Alberti P; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S63-S73. PubMed ID: 31647152
[TBL] [Abstract][Full Text] [Related]
99. Potential clinical applications of halichondrins in breast cancer and other neoplasms.
Ortega V; Cortés J
Breast Cancer (Dove Med Press); 2012 Feb; 4():9-19. PubMed ID: 24367189
[TBL] [Abstract][Full Text] [Related]
100. Risk Factors for Eribulin-induced Severe Neutropenia in Patients With Recurrent Breast Cancer.
Takada S; Hosokawa Y; Umehara K; Kimura Y; Fukai Y; Shikishima K; Yamamoto M; Maeda H; Tomioka N; Watanabe K; Hashishita H
In Vivo; 2024; 38(1):500-505. PubMed ID: 38148090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]